Lipid formulations of amphotericin B: clinical efficacy and toxicities.

@article{WongBeringer1998LipidFO,
  title={Lipid formulations of amphotericin B: clinical efficacy and toxicities.},
  author={Annie Wong-Beringer and Richard H. A. H. Jacobs and B. Joseph Guglielmo},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={1998},
  volume={27 3},
  pages={603-18}
}
Commercially available lipid formulations of amphotericin B (Abelcet, Amphotec, and AmBisome) represent a significant advance in drug delivery technology. Differences in biochemical, pharmacokinetic, and pharmacodynamic properties among the lipid products have been shown in in vitro and in vivo models. Clinical experience with these products has been primarily in patients either refractory to or intolerant of conventional amphotericin B deoxycholate (AmBd). None of the lipid-based products… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 95 extracted citations

Similar Papers

Loading similar papers…